<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7077276/results/search/test_trace/results.xml">
  <result pre="activities [19]. However, there are very few reports of PCV2" exact="infection" post="inhibition available for pertaining to such natural small molecule"/>
  <result pre="the most complicated and principal constituent, possessing the activity against" exact="infection" post="of several viruses, such as human immunodeficiency virus (HIV)"/>
  <result pre="activity are complicated and diverse, depending on the specific virus" exact="infection" post="process or host cell response, one of which is"/>
  <result pre="was calculated according to the Reed-Muench method. The multiplicity of" exact="infection" post="(MOI) was defined as the number of plaques forming"/>
  <result pre="present during whole PCV2 infection. The infected cells without EGCG" exact="treatment" post="was set as mock control. TCID50 was determined at"/>
  <result pre="= 1.0 at 37 °C, followed by 100 μM EGCG" exact="treatment" post="maintained for 4 h, 12 h and 24 h,"/>
  <result pre="of PCV2 was significantly inhibited at the 100 μM EGCG" exact="treatment" post="during the whole infective process, the virus titer of"/>
  <result pre="process, the virus titer of PCV2 infected cells with EGCG" exact="treatment" post="showed a significant decrease at various time points compared"/>
  <result pre="decrease at various time points compared to that without EGCG" exact="treatment" post="(Figure 1c). Inhibition of PCV2 infectivity was also manifested"/>
  <result pre="the 100 μM EGCG treatment. The inhibitory effect of PCV2" exact="infection" post="was still detectable for the 10 μM EGCG treatment"/>
  <result pre="PCV2 infection was still detectable for the 10 μM EGCG" exact="treatment" post="(Figure 1d,e). Furthermore, the cells infected with PCV2 at"/>
  <result pre="of the PCV2 infected cells with the 100 μM EGCG" exact="treatment" post="was obviously lower than that without EGCG treatment (Figure"/>
  <result pre="μM EGCG treatment was obviously lower than that without EGCG" exact="treatment" post="(Figure 1f). The original catechin EC displayed no considerable"/>
  <result pre="EC displayed no considerable anti-infective effect on PCV2 under similar" exact="treatment" post="conditions (Figure 1c–f). In addition, the EC50 of the"/>
  <result pre="results showed that compared with of the EGCG whole process" exact="treatment" post="PCV2 infection, a significant inhibitory effect could not be"/>
  <result pre="infection, a significant inhibitory effect could not be detected with" exact="treatment" post="for 4 h or 12 h after PCV2 infection,"/>
  <result pre="infection, only a slight effect was observed when the post" exact="treatment" post="duration reached 24 h (Figure 3a), indicating that EGCG"/>
  <result pre="indicating that EGCG might work at the early stage of" exact="infection" post="course. Thereby, the binding assay was performed, the virions"/>
  <result pre="PCV2 particles would decrease significantly in cells with the EGCG" exact="treatment" post="measured by qRT-PCR (Figure 3b). The cells attached by"/>
  <result pre="dropped from ~70% to ~55% in cells with the EGCG" exact="treatment" post="for 1 h (Figure 3c). This tendency was also"/>
  <result pre="eventually lead to the inability of virions to complete the" exact="infection" post="process [18]. We next performed the infectivity assay of"/>
  <result pre="the infectivity assay of mutant viruses with 100 μM EGCG" exact="treatment" post="during the whole infective process. The titers of mutant"/>
  <result pre="antiviral effect of EGCG could not be detected during the" exact="infection" post="of PCV2 (D70A) and PCV2 (D78A) (Figure 7g,i), These"/>
  <result pre="showed that EGCG exhibited an inhibitory effect on the PCV2" exact="infection" post="at the concentration of 100 μM, without causing significant"/>
  <result pre="showed similar antiviral activity against various viruses, EGCG inhibited the" exact="infection" post="of PRRSV with an EC50 of 48.2–63.09 μM in"/>
  <result pre="at this stage is not of practical value in the" exact="treatment" post="of clinical virus infections, the identification of key amino"/>
  <result pre="porcine circovirus and porcine parvovirusJ. Comp. Pathol.199912111110.1053/jcpa.1998.029510373289 8.SanchezR.E.Jr.NauwynckH.J.McNeillyF.AllanG.M.PensaertM.B.Porcine circovirus 2" exact="infection" post="in swine foetuses inoculated at different stages of gestationVet."/>
  <result pre="of (-)-epigallocatechin-3-gallate (EGCG) against porcine reproductive and respiratory syndrome virus" exact="infection" post="in vitroAntivir. Res.2018158526210.1016/j.antiviral.2018.07.01230048655 44.WangC.Y.HourM.J.LaiH.C.ChenC.H.ChangP.J.HuangS.H.LinC.W.Epigallocatechin-3-gallate inhibits the early stages of"/>
  <result pre="genome copies were measured by real-time PCR. (f) Indirect IFA" exact="detection" post="of PCV2 infected cells. (g) Dose response curve and"/>
  <result pre="with PCV2 at MOI = 1.0 with 100 μM EGCG" exact="treatment" post="during all the phases, or followed by post-treatment of"/>
  <result pre="mutant viruses at MOI = 1.0 with 100 μM EGCG" exact="treatment" post="during the whole infective process and the titers were"/>
 </snippets>
</snippetsTree>
